Latest & greatest articles for knee osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on knee osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on knee osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for knee osteoarthritis

102. Viscosupplementation for Knee Osteoarthritis

Viscosupplementation for Knee Osteoarthritis Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Viscosupplementation for Knee Osteoarthritis: Clinical Evidence and Guidelines DATE

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

104. Effectiveness of a cognitive-behavioural group intervention for knee osteoarthritis pain: A randomized controlled trial

Effectiveness of a cognitive-behavioural group intervention for knee osteoarthritis pain: A randomized controlled trial 25413168 2015 09 04 2016 06 27 2015 09 04 1477-0873 29 9 2015 Sep Clinical rehabilitation Clin Rehabil Effectiveness of a cognitive-behavioural group intervention for knee osteoarthritis pain: a randomized controlled trial. 868-81 10.1177/0269215514558567 To assess the effectiveness of a six week cognitive-behavioural group intervention in patients with knee osteoarthritis (...) pain. Single-blinded randomized controlled trial. Primary care providers in a medium-sized city in Finland. A total of 111 participants aged from 35 to 75 with clinical symptoms and radiographic grading (Kellgren-Lawrence 2-4) of knee osteoarthritis were included. In the intervention group, 55 participants attended a cognitive-behavioural training programme for pain management with six weekly group sessions supervised by a psychologist and a physiotherapist. Concurrently, they and the 56

EvidenceUpdates2015

105. Intra-Articular Hyaluronic Acid for Osteoarthritis of the Knee

Intra-Articular Hyaluronic Acid for Osteoarthritis of the Knee Intra-articular hyaluronic acid for osteoarthritis of the knee Intra-articular hyaluronic acid for osteoarthritis of the knee BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation BlueCross BlueShield Association. Intra-articular hyaluronic acid for osteoarthritis of the (...) knee. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 29(6). 2014 Authors' objectives To determine whether available evidence demonstrates IAHA provides clinically meaningful improvement in pain and function compared with placebo in patients with knee OA; to examine the potential harms of IAHA; and to assess whether net health outcomes are improved. Authors' conclusions A large body of evidence obtained from randomized controlled trials has examined the effect of IAHA on pain

Health Technology Assessment (HTA) Database.2015

106. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial

Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial 26705327 2016 03 18 2016 07 22 2016 12 15 1462-0332 55 4 2016 Apr Rheumatology (Oxford, England) Rheumatology (Oxford) Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial. 755-62 10.1093/rheumatology/kev426 This trial aimed to test the effectiveness of a wearable pulsed electromagnetic fields (PEMF) device (...) in the management of pain in knee OA patients. In this randomized [with equal randomization (1:1)], double-blind, placebo-controlled clinical trial, patients with radiographic evidence of knee OA and persistent pain higher than 40 mm on the visual analog scale (VAS) were recruited. The trial consisted of 12 h daily treatment for 1 month in 60 knee OA patients. The primary outcome measure was the reduction in pain intensity, assessed through VAS and WOMAC scores. Secondary outcomes included quality

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

107. Systematic review with meta analysis: In knee osteoarthritis, pharmacological interventions, with the exception of acetaminophen, significantly improve pain; with intra-articular administration being more effective

Systematic review with meta analysis: In knee osteoarthritis, pharmacological interventions, with the exception of acetaminophen, significantly improve pain; with intra-articular administration being more effective In knee osteoarthritis, pharmacological interventions, with the exception of acetaminophen, significantly improve pain; with intra-articular administration being more effective | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our (...) use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In knee osteoarthritis, pharmacological interventions, with the exception of acetaminophen, significantly improve

Evidence-Based Medicine (Requires free registration)2015

108. Systematic review with meta-analysis: Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis

Systematic review with meta-analysis: Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis Article Text Therapeutics/Prevention Systematic review with meta-analysis Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis David Felson 1 , 2 Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2015

109. Surgical Management of Osteoarthritis of the Knee

Surgical Management of Osteoarthritis of the Knee 1 * See Appendix XIII for details regarding support SURGICAL MANAGEMENT OF OSTEOARTHRITIS OF THE KNEE EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors 12.4.15 Supported* by: Endorsed by: 2 Disclaimer This Clinical Practice Guideline was developed by an AAOS physician volunteer Guideline development group based on a systematic review of the current scientific and clinical (...) Surgeons 3 To View All AAOS Evidence-Based Guidelines and Appropriate Use Criteria in a User-Friendly Format, Please Visit the Orthoguidelines Web- Based App at www.orthoguidelines.org or by clicking the icon above! 4 SUMMARY OF RECOMMENDATIONS The following is a summary of the recommendations of the AAOS Clinical Practice Guideline on the Surgical Management of Osteoarthritis of the Knee. All readers of this summary are strongly urged to consult the full guideline and evidence report

American Academy of Orthopaedic Surgeons2015

110. Osaflexan (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

Osaflexan (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/17 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 OSAFLEXAN 1178 mg, oral powder for solution in single-dose sachets Box of 30 single-dose sachets (CIP: 34009 397 018 2 0) Box of 90 single-dose sachets (CIP: 34009 575 860 6 5) Applicant: ROTTAPHARM S.A.R.L. INN Glucosamine (sulfate) ATC code (2012 (...) ) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 10 March 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) B/30 only Hospital use (French Public Health Code L.5123-2) B/30 and 90 Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." HAS - Medical, Economic and Public Health

Haute Autorite de sante2014

111. Structoflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Structoflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/13 TRANSPARENCY COMMITTEE Opinion 20 November 2013 STRUCTOFLEX 625 mg, hard capsule Box of 60 hard capsules (CIP: 34009 346 919 2) Applicant: PIERRE FABRE MEDICAMENT INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason for the review Re-assessment of the actual benefit (...) pursuant to the findings of the Transparency Committee in its opinion of 30 June 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123-2) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." The legally binding text is the original French version HAS - Medical, Economic and Public Health Assessment Division 2/13 Actual Benefit Insufficient Actual Benefit Therapeutic Use Due

Haute Autorite de sante2014

112. Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/8 The legally binding text is the original French version TRANSPARENCY C OMMITTEE Opinion 20 November 2013 VOLTAFLEX 625 mg, film-coated tablet B/60 tablets (CIP: 34009 384 573 2) Applicant: NOVARTIS SANTÉ FAMILIALE S.A.S. INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason (...) for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 10 March 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." HAS - Medical, Economic and Public Health Assessment Division 2/8 Actual Benefit Insufficient Actual Benefit Therapeutic Use Due to the very modest efficacy on pain and functional disability

Haute Autorite de sante2014

113. Flexea (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Flexea (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/17 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 FLEXEA 625 mg, tablet Box of 60 tablets (CIP: 34009 380 534 2 5) Box of 180 tablets (CIP: 34009 380 535 9 3) Applicant: EXPANSCIENCE INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory (...) drugs) Reason for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 22 July 2009. List(s) concerned National Health Insurance (French Social Security Code L.162-17) only for the box of 60 Hospital use (French Public Health Code L.5123-2) for boxes of 60 and 180 Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee.” HAS - Medical, Economic and Public Health Assessment Division 2/17 AB

Haute Autorite de sante2014

114. Dolenio (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

Dolenio (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/12 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 DOLENIO 1178 mg, film-coated tablets Box of 30 tablets (CIP: 34009 393 133 1) DOLENIO 1178 mg, tablets in blister pack Box of 30 tablets (CIP: 34009 496 655 0) Applicant: BIOCODEX INN Glucosamine (sulfate) ATC code (2012) M01AX05 (other non-steroidal (...) anti-rheumatic anti-inflammatory drugs) Reason for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 13 January 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123-2) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee. " HAS - Medical, Economic and Public Health Assessment Division 2/12 Actual Benefit

Haute Autorite de sante2014

115. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines

Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation CADTH. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Nine systematic reviews and eight evidence-based guidelines were identified regarding viscosupplementation for the treatment of patients with osteoarthritis of the knee. Final publication URL Indexing Status

Health Technology Assessment (HTA) Database.2014

116. 45-day mortality after 467 779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study.

45-day mortality after 467 779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study. BACKGROUND: Understanding the risk factors for early death after knee replacement could help to reduce the risk of mortality after this procedure. We assessed secular trends in death within 45 days of knee replacement for osteoarthritis in England and Wales, with the aim of investigating whether any change that we recorded could be explained (...) by alterations in modifiable perioperative factors. METHODS: We took data for knee replacements done for osteoarthritis in England and Wales between April 1, 2003, and Dec 31, 2011, from the National Joint Registry for England and Wales. Patient identifiers were used to link these data to the national mortality database and the Hospital Episode Statistics database to obtain details of death, sociodemographics, and comorbidity. We assessed mortality within 45 days by Kaplan-Meier analysis and assessed

Lancet2014

117. Prolotherapy: A nontraditional approach to knee osteoarthritis

Prolotherapy: A nontraditional approach to knee osteoarthritis Prolotherapy: A nontraditional approach to knee osteoarthritis Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Prolotherapy: A nontraditional approach to knee osteoarthritis View/ Open Date 2014-04 Format Metadata Abstract Recommend prolotherapy (...) for patients with knee osteoarthritis (OA) that does not respond to conventional therapies. URI Part of Citation Journal of Family Practice, 63(4) 2014: 206-208 Collections hosted by hosted by

PURLS2014

118. Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections

Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections Prescrire IN ENGLISH - Spotlight ''Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections '', 1 October 2013 {1} {1} {1} | | > > > Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  (...) Spotlight Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections At best, intra-articular hyaluronic acid injections give modest relief to patients suffering knee osteoarthritis pain, at the price of local reactions and sometimes severe adverse effects. In patients suffering knee osteoarthritis pain, above all treatment involves physical exercises and analgesics, chiefly paracetamol. Intra-articular hyaluronic acid injections are sometimes offered, but there is no proof

Prescrire2014

119. Transcutaneous electrical nerve stimulation as an adjunct to education and exercise for knee osteoarthritis: a randomized controlled trial

Transcutaneous electrical nerve stimulation as an adjunct to education and exercise for knee osteoarthritis: a randomized controlled trial 23983090 2014 03 04 2014 04 22 2014 03 04 2151-4658 66 3 2014 Mar Arthritis care & research Arthritis Care Res (Hoboken) Transcutaneous electrical nerve stimulation as an adjunct to education and exercise for knee osteoarthritis: a randomized controlled trial. 387-94 10.1002/acr.22147 To determine the additional effects of transcutaneous electrical nerve (...) stimulation (TENS) for knee osteoarthritis (OA) when combined with a group education and exercise program (knee group). The study was a randomized, sham-controlled clinical trial. Patients referred for physiotherapy with suspected knee OA (confirmed using the American College of Rheumatology clinical criteria) were invited. Exclusion criteria included comorbidities preventing exercise, previous TENS experience, and TENS contraindications. Prospective sample size calculations required 67 participants

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro